|
Diagnostic Integrated Program Team (IPT) under Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE)
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
Integrated Program Teams (IPT) are established by the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). This IPT is focused on diagnostics related to medical countermeasures requirements and development.
|
|
Diet-Induced Hypomethylation in Preneoplastic Liver
|
Research Initiative
|
FDA
|
NCI
|
The Food and Drug Administration (FDA), the National Center for Toxicological Research, and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies.
|
|
Dietary Supplement Ingredient Database (DSID)
|
Research Initiative
|
CDC, FDA
|
OD/DPCPSI/ODS
|
The NIH Office of Dietary Supplements (ODS) leads this program, which provides a database of basic information about the nutrient content of selected ingredients in commonly consumed types of dietary supplements, compared to label-reported ingredient levels. ODS, with collaboration from USDA, develops and maintains this database of statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently, the Dietary Supplements Ingredient Database (DSID) provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Ingredients studied include children’s multivitamin/mineral supplements, non-prescription prenatal supplements, and omega-3 fatty acids. Additional dietary supplement ingredients will be included in future releases of the database.
|
|
Dietary Supplement Label Database (DSLD)
|
Resource Development
|
CDC, FDA
|
OD/DPCPSI/ODS
|
In response to a congressional mandate, the NIH Office of Dietary Supplement (ODS), in collaboration with NLM, takes the lead on the development and maintenance of the Dietary Supplements Label Database (DSLD). The database now contains over 85,000 labels, with new data accumulating at the rate of 1,000 labels per month. The DSLD will grow to include nearly all of the dietary supplement products in the United States. All labels are verified yearly to ensure they remain current. The DSLD provides product information that can be organized and searched by users. The primary users of this database are researchers who use the DSLD to help determine total nutrient intakes from food and supplements in populations they study. Health care providers use it to find the content of products their patients are taking.
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
CC
|
This project is a collaboration between the National Institutes of Health (NIH )Clinical Center and the Food and Drug Administration (FDA)that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis, and therapy monitoring of marrow disorders.
|
|
Drug Induced Liver Injury Network (DILIN)
|
Resource Development
|
FDA
|
NIDDK
|
Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of the Food and Drug Administration (FDA) serve as ad hoc members on the committee overseeing the network activities.
|
|
Early Hearing Detection and Intervention
|
Meeting/ Workshop
|
CDC, HRSA
|
NIDCD
|
This is Federal collaboration program involving the National Institute on Deafness and Other Communication Disorders (NIDCD), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA). NIDCD collaborates on early identification and diagnosis of hearing loss and intervention services for newborns and infants. HRSA funds awards to states and healthcare providers to screen newborns and young children for hearing loss. CDC funds states to develop data systems to track hearing loss. NIDCD also funds research grants to scientists throughout the US to study early hearing detection and intervention services.
|
|
East Asia Viral Hepatitis and Liver Cancer Consortium
|
Other
|
CDC
|
NCI, NIAID, NIDDK
|
The consortium aims to coordinate and share human, financial, and technical resources to effectively and efficiently address research and public health action needs in the prevention and control of viral hepatitis and liver cancer. This is a trans-HHS collaboration working with the World Health Organization Western Pacific Region Office WHO/WPRO and Ministries of Health of several partner countries.
|
|
Ebola Clinical Research Response in Democratic Republic of the Congo
|
Research Initiative
|
FDA
|
NIAID
|
This is a research collaboration between the National Institutes of Health (NIH), the Food and Drug Administration (FDA),and the Democratic Republic of the Congo (DRC) to respond to the Ebola outbreak in the DRC.
|
|
Ebola Clinical Research Response in West Africa
|
Research Initiative
|
CDC, FDA
|
NIAID
|
This is a research collaboration between the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC) to respond to the Ebola emergency in West Africa.
|